Terapéutica sustitutive con buprenorfina para abusadores/adictos a opiáceos.

Saved in:
Bibliographic Details
Title: Terapéutica sustitutive con buprenorfina para abusadores/adictos a opiáceos.
Alternate Title: Substitution treatment with buprenorphine for opiate abusers/addicts.
Authors: Machorro Mario, Souza y souzaym@prodigy.net.mx, Barriga Salgado Lino, Diaz, Cruz Victor Manuel, Guisa
Source: Revista Mexicana de Neurociencia. jul/ago2007, Vol. 8 Issue 4, p386-405. 20p. 5 Charts.
Subjects: DRUG abuse, ADDICTIONS, BUPRENORPHINE, TREATMENT programs, HARM reduction
Abstract (English): This paper presents a thematic revision of the substitution treatment with buprenorphine, BPNA, for opiate abusers/addicts, which shows the current clinical situation of abuse and addiction to opiates (natural and synthetic), their main effects and other pharmacologic antecedents. The succinct description of the urgent wish-necessity of consumption, D-NIC (craving) and its searching conduct for the substance, bases the clinical context and the necessary professional management for this issue. BPNA is described as the substance of first election in substitute management of certain patients, its pertinent characteristics and recommendations for ambulatory administrationism pharmacology and pharmacokinetic, clinical use, opiate gradual reduction as goal for management of chosen users, the use of opiate antagonists and medical management of abstinence; psychotherapeutic modalities available around the Relapse Prevention Program, and if it is the case, the confined management of patients through a special treatment (Therapeutic Community). The documented convenience of its use is discussed, comparing it with methadone hydrochloride, MH, used at the moment in many programs for the treatment of opiates abusers/addicts around the world; the paper concludes with the revision of advantages/disadvantages of the use of BPNA. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Este comunicado presenta una revision tematica del tratamiento sustitutivo con bupenorfina, con buprenorfina, BPNA, para abusadores/adictos a opiaceos, que muestra la situacion clinica actual del abuso y dependencia de los opiaceos (naturales y sintéticos), sus principales efectos y demás antecedentes farmacológicos, como base para la compresion del manejo de esta particularmente grave condicion adictiva. La description sucinta del deseo-necesidad imperiosa de consumo, D-NIC (craving) y su conducta de búsqueda de la sustancia, fundamenta el contexto clinico y el necesario manejo profesional que debe recibir esa entidad. Más adelante se describe la BPNA como sustancia de primera eleccion, la farmacologia y farmacocinetica, uso clinico, reduccion gradual opiacea como meta de manejo de usuarios legidos; uso de antagonistas opiaceos y manejo médio de la abstinencia; modalidades psicoterapeuticas disponibles en torno al Programa de Prevencion de recaidas, y en su caso, el manejo confinado de los pacientes a través de una modalidad de abordaje especial (Comunidad Terapéutica). Se discute la conveniencia documentada de su uso, contrastándola con el clorhidrato de metadona, (CM), utilizado actualmente en muchos programas de manejo de abusadores/adictos a opiáceos en el mundo y se concluye con la revision de las ventajas/desventajas del uso de BPNA e incluso de sus efectos colaterales. [ABSTRACT FROM AUTHOR]
Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Be the first to leave a comment!
You must be logged in first